{"id":"W2986700515","doi":"10.1056/nejmoa1912388","title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2967,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Heart Institute","funders":"Canadian Institutes of Health Research; Abbott Vascular; Esperion Therapeutics; Heart Research Institute; Bausch Health; Duke Clinical Research Institute; Eisai; Daiichi Sankyo Europe; Gilead Sciences; Servier; University of Glasgow; AstraZeneca; Amarin Corporation; Singulex; Ionis Pharmaceuticals; TG Therapeutics; Massachusetts Medical Society; Boston Scientific Corporation; Kowa Company; Sanofi; Institut de Cardiologie de Montréal; Celgene; Pfizer; Biogen; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Colchicine; Gout; Medicine; Pericarditis; Myocardial infarction; Inflammation; Pharmacology; Internal medicine; Cardiology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}